MCL1 and prostate carcinoma: Significantly, MARCH5 depletion prevented the decrease in MCL1 by erlotinib and cabozantinib (C-MET/VEGFR2 inhibitor) in LNCaP cells (Figure 3A,B), and in other prostate cancer cells (PC3 and DU145 cells) (Figure 3C, Figure 3—figure supplement 1M), indicating that the decreases in MCL1 by these kinase inhibitors are mediated by MARCH5.